Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug...
China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration...
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...
Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8...
China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical...
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received marketing approval...
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...
Bayer (ETR: BAYN) has submitted a marketing application to the European Medicines Agency (EMA) for...
Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...
China’s CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration...
German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...
China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...
Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...
Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...